Business News • PR NewsWire • Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole

LEUVEN, Belgium, August 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has...

View More : http://www.prnewswire.com/news-releases/germanys-iqwig-confirms-that-thrombogenics-jetrea-demonstrates-major-added-value...

Releted News by prnewswire

Beijing und Houston verbunden

Fingerprints Offers Unique, Personalised Wedding Jewellery and Keepsakes